Puma Biotech (PBYI) Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer Did not Achieve OS Statistical Significance but Trended Positively
Tweet Send to a Friend
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced top line results from the Phase III NALA trial of the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
